11 17
1 15 15 11 3a
19 19 31 19 19 18

27 Neha Vapiwala, MD

1 19 19 31 19 65 19 19 49 31 31 19 19 19 19 19 45
3b
19 19 19 1 1 1 1 2d
8f Neha Vapiwala photo 2f
47

Eli Glatstein Professor in Radiation Oncology

18

74 Department: Radiation Oncology

11 13
7
1 1 5
1 18
e
25

Contact Information

c

3f 3400 Civic Center Boulevard
28 Department of Radiation Oncology
20 4th Floor, West Pavilion
5b
Philadelphia, PA 19104 c5
Office: 215-662-2337
Fax: 215-349-8975
Email: vapiwala@uphs.upenn.edu

13
5 e
1e

Publications

6e

Pubmed Link

b
9 e
17

Links

d b
9 12
1b

Education

d
    1d
  • 43 BA (Biology and Hispanic Studies) 54
    Johns Hopkins University, 1999
    • 1d
  • 2f MD (Medicine) 56
    University of Pennsylvania, 2002
    • 1a
b
b
1 5
1 1 1 2b

Description of Research Expertise

bb

prostate cancer, bladder cancer, image-guided radiation therapy, biologic agents, radiosensitizers, novel imaging agents, external beam radiation, immunotherapy, medical education

1 2b

Description of Clinical Expertise

70

prostate cancer, bladder cancer, testicular cancer, image-guided radiation therapy, integrative medicine

1 28

Description of Other Expertise

2d1

Dr. Neha Vapiwala is Professor and Vice Chair of Education in the Department of Radiation Oncology at University of Pennsylvania. She specializes in the management of patients with genitourinary (GU) cancers. Her work focuses on biological and technological improvements in the delivery of photon- and proton-based radiation, and she currently serves as the Principal Investigator of multiple therapeutic trials for prostate cancer patients, including a recently activated national phase III randomized clinical trial on the use of PET scan findings to direct and local and systemic treatment intensification in patients with post-prostatectomy biochemical recurrence through the ECOG-ACRIN cooperative group.
8
1ee Dr. Vapiwala is a member of numerous national and international scientific committees dedicated to GU cancer research and education, including the American Society of Clinical Oncology (ASCO) and American Society of Radiation Oncology (ASTRO) Scientific Program Committees and the National Cancer Institute's Prostate Cancer Task Force. She was recently elected to the Board of Directors of ASTRO and named to the editorial boards of JAMA Oncology and the Journal of Clinical Oncology.
8
1d0 Dr. Vapiwala also devotes significant time to her roles in medical education. She previously served as Assistant Dean of Student Affairs and was named the Associate Dean of Admissions at University of Pennsylvania’s Perelman School of Medicine in 2019. She is also the current Chair of the Accreditation Council for Graduate Medical Education's Residency Review Committee for Radiation Oncology, which oversees national training standards for her specialty.

1 1 1f

Selected Publications

5
    5
  • da Hussain M, Lin D, Saad F, Vapiwala N, Chapin BF, Sandler H, Evans CP, Carducci MA, Sachdev S. : Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat? 38 J Clin Oncol 39(1) : 13-16, Jan 2021
    • 5
  • 134 Valle L, Shabsovich D, de Meerleer G, Maurer T, Murphy DG, Nickols NG, Vapiwala N, Calais J, Kishan AU : Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review 39 European Urology Oncology June 2021
    • 5
  • 15e Vapiwala N, Wong JK, Handorf E, Paly J, Grewal A, Tendulkar R, Godfrey D, Carpenter D, Mendenhall NP, Henderson RH, Stish BJ, Vargas C, Salama JK, Davis BJ, Horwitz EM : A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients 36 Int J Rad Onc Bio Phys July 2021
    • 5
  • 82 Vapiwala N : The Power of Exercise to Influence Cardiovascular and Oncologic Outcomes-Survival of the Fittest 2c JAMA Oncol August 2021
    • 5
  • fb Butala AA, Huang CC, Bryant CM, Henderson RH, Hoppe BS, Mendenhall NP, Vapiwala N, Mailhot Vega RB. : Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity 2b Value Health Mar 2022
    • 5
  • 91 Kamran SC, Winkfield KM, Reede JY, Vapiwala N. : Intersectional Analysis of U.S. Medical Faculty Diversity over Four Decades 3a N Engl J Med 386 : 1363-1371, Apr 2022
    • 5
  • 273 Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE; Prostate Cancer Cellular Therapy Program Investigators, Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB. : PSMA-targeting TGFbeta-insensitive armored CAR T-cells in metastatic castration-resistant prostate cancer: a phase 1 trial 26 Nat Med Mar 2022
    • 5
  • d2 Meghani SH, Quinn R, Robinson A, Chittams J, Vapiwala N, Naylor M, Cheatle M, Knafl GJ. : Trajectories and predictors of high-occurrence pain flares in ambulatory cancer patients on opioids 3c JNCI Cancer Spectr 8 : pkae003, Jan 2024
    • 5
  • ac Ennis RD, Corn BW, Krug S, Vapiwala N, Hoffe SE. : Decision Making in Health Care: Embracing the Real People Comprising the Patient-Doctor Relationship 2e JCO Oncol Pract Jan 2024
    • 5
  • 1f8 Hamstra DA, Dignam JJ, Bruner DW, Michaelson MD, Bachand F, Master V, Torres MA, Saylor PJ, Wallace RE, Vapiwala N, Efstathiou JA, Roach M 3rd, Rosenthal SA, Raben A, Morgan SC, Kavadi VS, Spratt DE, Michalski JM, Seiferheld W, Pugh SL, Movsas B, Sandler H. : Phase III trial of dose escalated radiation therapy and standard androgen deprivation therapy (ADT) vs. dose escalated radiation therapy and enhanced ADT with orteronel for men with high-risk prostate cancer (NRG/RTOG 1115) 3b Int J Radiat Oncol Biol Phys Jul 2025
    • 6
1 1 19 1b
11 15 11 15 25 11 11 11 18
9 13